What are the real risks of taking Mounjaro?

What side effects do most people actually experience on Mounjaro?

The majority of side effects reported in clinical trials and in real-world use are gastrointestinal. Nausea tends to be the most common, followed by vomiting, diarrhoea, constipation, indigestion, reflux and burping. Fatigue, headache and dizziness are also reported, particularly around the time of starting treatment or moving to a higher dose. Injection-site reactions (mild redness or discomfort at the site of the weekly injection) occur in a smaller proportion of patients.

A question our prescribers hear most weeks is whether these effects ever go away. For most people, they do. The pattern is typically most noticeable in the first one to two weeks after a dose change, then fades as the body adjusts. The titration schedule exists partly for this reason: starting at 2.5 mg gives the body time to adapt before the dose increases. You can read a fuller breakdown, including less common effects, on the Mounjaro side effects page.

The NHS medicines page for tirzepatide lists side effects by frequency and explains which ones to report to a prescriber. It is a useful reference to have alongside your Patient Information Leaflet, which accompanies every pen.

Which risks of Mounjaro are serious enough to warrant urgent care?

Serious adverse events are less common, but they matter. Pancreatitis sits at the top of this list. In January 2026, the MHRA's Drug Safety Update confirmed that acute pancreatitis is a known (if infrequent) risk with GLP-1 medicines including tirzepatide. The warning sign to act on is severe stomach pain, particularly pain that spreads into the back, with or without vomiting. If that happens, stop the injection and get emergency medical help; do not wait to see whether it settles.

Gallbladder problems, including gallstones and inflammation, have also been reported. Symptoms include pain in the upper right abdomen, sometimes with fever or yellowing of the skin. Dehydration from prolonged vomiting or diarrhoea can strain the kidneys, so staying well hydrated during any GI illness matters. Allergic reactions (swelling, rash, difficulty breathing) are rare but require immediate attention. There is also a small signal around changes in heart rate, and anyone wanting to understand what Mounjaro means for stroke risk will find the evidence covered in detail on that dedicated page. The pancreatitis risk with Mounjaro page goes into more detail on that specific concern.

Separate to physical harms, some people report low mood or changes in mental wellbeing on GLP-1 medicines. The MHRA continues to monitor this signal. Tell your prescriber if your mental health changes after starting Mounjaro.

Are there groups of people for whom the risk of Mounjaro is higher?

Some medical histories raise the threshold for prescribing tirzepatide or rule it out altogether. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) is a contraindication: animal studies raised a signal, and the medicine is not used where this risk exists. A history of pancreatitis, or certain inflammatory bowel conditions, also requires careful prescriber consideration. The question of Mounjaro and cancer risk is one that often comes up in consultations, and the evidence there is worth reading separately.

Mounjaro is not recommended in pregnancy, for those breastfeeding, or for anyone who is trying to conceive. The medicine is also not licensed for anyone under 18. For women using oral contraceptives, there is a specific interaction to be aware of: for the first four weeks of treatment and for four weeks after each dose increase, an additional non-oral method of contraception (such as condoms) is recommended, because Mounjaro's effect on gastric emptying can reduce pill absorption. This is covered in detail on the Mounjaro and pregnancy risk page.

People with a recent history of serious cardiovascular events should discuss suitability carefully with a prescriber. BMI and comorbidities shape the benefit-risk balance for each individual, which is why clinical assessment is the starting point, not a workaround. Explore the broader risk profile of Mounjaro if you want a fuller picture before your consultation.

When should you contact a doctor or pharmacist, and how do you report a problem?

Mild nausea after a new dose is expected and can usually be managed with small meals, adequate hydration and rest. That is not the moment to call for help. The signals that do need prompt attention: severe abdominal pain (especially radiating to the back), persistent vomiting that prevents you from keeping fluids down, signs of a serious allergic reaction, sudden changes in vision, or any chest symptoms.

If you are unsure, contact your prescriber or call NHS 111. In an emergency, call 999. Mounjaro carries a Black Triangle (▼) status in the UK, which means the MHRA actively collects safety data on it. You can contribute to that process (and to patient safety more broadly) by reporting any suspected side effect through the MHRA Yellow Card scheme. Reports from patients are taken as seriously as those from clinicians.

At nume, aftercare is available seven days a week. If a side effect concerns you between orders, our team is reachable via the contact page. A prescriber discusses suitability and potential side effects as part of the free consultation, that conversation is the right place to raise anything you're uncertain about before treatment begins. You can check your eligibility and start a free consultation at any point.